On March 6, Novo Nordisk China R & D Center announced the launch of INNOVO Innovation Open Platform in Beijing, aiming at building a new ecology of R & D cooperation in pharmaceutical innovation and accelerating the transformation of scientific research results into innovative drug R & D through an open innovation cooperation model and joint efforts with China's local biomedical innovation force.
2019 marks the 25th anniversary of Novo Nordisk's business operation in China, when it chose to launch an open innovation platform, reflecting the upgrading of Novo Nordisk's innovation model and the importance it attaches to the Chinese market.Pharmcube was invited to the launch ceremony of the INNOVO Open Innovation Platform to share some information on the INNOVO platform's cooperative operation model and Novo Nordisk's global R & D strategy.
What is INNOVO?
With the deep implementation of the national "innovation-driven development" strategy and the continuous improvement of the innovation strength of the Chinese pharmaceutical industry, China has become one of the most active pharmaceutical markets in the world.On the policy level, the approval efficiency of Chinese drug regulatory agencies has increased significantly in recent years, and new drug investment has withdrawn.Medicare payment.The path of market access is also dredging, which has injected vitality into the development of the Chinese pharmaceutical industry.As a number of innovative drug companies began to enter the harvest period and innovative drugs were approved for marketing, more and more excellent entrepreneurs and start-ups are emerging.
China's "great" pharmaceutical industry has naturally attracted global attention, which can only be felt when Chinese companies have become the norm in cross-border cooperation in innovative drugs.As one of the established pharmaceutical giants that have been rooted in the Chinese market for many years, Novo Nordisk has established an R & D center in China earlier. This time, INNOVO initiated by Novo Nordisk China R & D Center is actually an open innovation and open platform, which is equivalent to Novo Nordisk's innovation in R & D mode. This marks that Novo Nordisk has been more focused on internal R & D since then and is willing to cooperate with the whole industry in a more open manner.
"Novo Nordisk's core contribution is to develop better medicines for patients who continue to innovate," Marcus Schindler, senior vice president of Global Drug Development at Novo Nordisk, said in an interview.We make long-term innovation investment in the search for the next generation of drugs, continuously improve the R & D capacity covering the complete value chain, and strengthen and supplement it through external cooperation to translate scientific ideas into tangible benefits for patients.We expect that INNOVO's open innovation model will be more effective in improving the efficiency of innovative drug development and meet the unmet medical needs of patients.
Marcus Schindler is also full of expectations for the operation of the INNOVO platform: "We must attract more external innovations from a global perspective, so that we can build very close partnerships with various partners, get good ideas and good technologies, and help us with scientific transformation.No matter where these ideas and technologies come from, we should consider working with them in depth, as long as they bring tangible benefits to patients.And we have accumulated a wealth of experience in selecting these ideas, and we can turn these ideas and technologies into products that can really benefit patients.Therefore, we believe that Novo Nordisk's INNOVO Open Innovation Platform will be the first platform for the company to truly cooperate systematically with external partners.On this platform we will invite a large number of scientists to join us.
What kind of partner does Novo Nordisk want?
In recent years, some pharmaceutical companies have actively explored and practiced open innovation.For example, Johnson & Johnson's JLABS, which settled in Zhangjiang in December 2017, replicates the operation model of its global open innovation platform and plans to accommodate nearly 50 innovative entities in the fields of life sciences and healthcare, attracting independent entrepreneurs or startup companies with which they are starting to work.Among domestic enterprises, the dream factory of Betta Pharmaceuticals can be said to be the same idea.
INNOVO has its own unique features.On the one hand, Novo Nordisk itself in diabetes.Hemophilia and other areas have a deeper accumulation, and is the first to establish R & D centers in China's multinational biopharmaceutical companies.In the operation of the INNOVO Open Innovation Platform, Novo Nordisk A/D China expects to rely on an in-depth understanding of the disease and patient situation.Strong preclinical and clinical experimental platform.The process development and production capacity of therapeutic proteins and peptides provide unique value to the partners.On the other hand, the INNOVO platform will focus on diabetes in the future.Obesity.Cardiovascular disease.Nonalcoholic steatohepatitis.Innovative discoveries in key disease areas such as chronic kidney disease and the search for protein engineering and agents.Innovative platforms and technologies related to oligonucleotide and stem cell therapy.
"Novo Nordisk China R & D Center is the first biomedical R & D institution established by a multinational drug company in China. It has sound scientific research capabilities in the field of drug R & D and has accumulated rich experience in early drug target discovery, validation, and molecular screening of drug candidates," said Su Jing, President of Novo Nordisk China R & D Center.Relying on INNOVO's open innovation platform, Novo Nordisk China R & D will act as an innovation accelerator to build academia.Medical institution.Biopharmaceutical companies.Incubators collaborate efficiently on innovative networks that continue to expand the boundaries of drug development.It is hoped that Novo Nordisk A/D China will be able to build the preferred R & D partner in the cost region through this platform.
In response to a reporter's question, Su Jing said: "INNOVO's partners include three broad categories, with different emphases."The cooperation with scientific research institutes is more about transforming scientific research results into innovative drugs.Working with startups is an overall push to mature projects into later stages of development.Cooperation with incubators is more about gathering and adding value to innovative resources.Su Jing also disclosed the operational objectives of INNOVO Open Innovation Platform, hoping to contact 100 partners in the first year and hope to export 3-5 projects in the next 3-5 years, and these projects can mature to the stage of further international development.
What does INNOVO mean for Novo Nordisk Global R & D?
If the business development strategies of other biopharmaceutical giants are summarized in "focus," Novo Nordisk should be summarized in "focus."Novo Nordisk is arguably the leading player in diabetes, with products including long-acting insulin.Premixed insulin.Faster acting insulin.GLP-1 and other major categories.Several other drugs for haemophilia and growth hormone disorders account for a relatively small proportion of Novo Nordisk's overall revenue.
Lars Fogh Iversen, Senior Vice President, Global Research Technologies, Novo Nordisk, told the INNOVO platform launch that Novo Nordisk still has a lot of R & D to do in diabetes.Diabetes affects some 425 million adults worldwide, and only a very small percentage of patients have their disease under control, he notes.There are still limited treatment options available, so there is still a lot of room for improvement.Novo Nordisk will continue to pursue opportunities for improvement and growth and will continue to study insulin.In the future, our research and development focus in the field of diabetes is to provide type 2 diabetes patients with weekly insulin injection products, as well as glucose-sensitive insulin.Insulin research remains central to Novo Nordisk's research.
In addition to insulin, Novo Nordisk's GLP-1 drugs are still in a steady state of rapid growth.As of November 2018, Novo Nordisk's insulin market share of global insulin accounted for 46.4 percent, an increase of 0.5 percent.The market share of GLP-1 products in diabetes drugs worldwide was 14.5%, an increase of 2.7 percentage points from the same period last year.Especially after entering the National Medical Insurance Catalogue in 2017, liraglutide has a relatively significant volume in the Chinese market. In 2018, sales revenue increased by 73% to 521 million DKK (about 82.5 million US dollars), which has accounted for 87% of the total market share of GLP-1 drugs in China and 1.3% of the total diabetes drug market.In addition, semaglutide, a long-acting GLP-1 receptor agonist, is Novo Nordisk's next brand.Novo Nordisk is also conducting studies in patients with type 1 diabetes, such as trying immunotherapy.Stem cell therapy for patients with type 1 diabetes.
But the Danish drug giant's interest in research and development has expanded more around diabetes.In addition to continuing to focus on diabetes research, Novo Nordisk is now focusing on obesity, Marcus Schindler said in an interview.Chronic diseases such as chronic kidney disease and non-alcoholic hepatitis are of increasing interest and continue to increase investment.So we need more partners who we hope will help us make new chemical discoveries and work with us to deliver better therapies.In addition, we are also very optimistic about the new technology of stem cell therapy, for which we need a lot of expert support, which is why we launched the INNOVO platform and external cooperation.
"We believe that building long-term sustainability.A win-win ecological system will be effective in stimulating innovation.The establishment of INNOVO Open Innovation Platform is the practice of Novo Nordisk's Partnership for Innovation in China, and will also provide stronger support for our global R & D strategy transformation.
As Zhou Xiaping, Novo Nordisk's global senior vice president and president of Greater China, said at the meeting: "The establishment of the INNOVO Open Innovation Platform is another initiative by Novo Nordisk to continue to expand its innovation ecosystem.Over the past 25 years, Novo Nordisk has been working on building omnidirectional.The great pattern of the ecosystem, together with partners, together to build the Great Wall of China to fight diabetes.In the future, we will work closely with each partner of INNOVO to push products to the market, so that ideas reach patients faster, and truly achieve 'co-creation.Share.Win-win '.